The medication is said to be the first and only fixed-dose combination of the short-acting secretagogue repaglinide and insulin sensitizer metformin HCl for the treatment of type 2 diabetes in the United States.
These agents include the [alpha]-glucosidase inhibitors acarbose and miglitol, the amylin analog pramlintide, the dipeptidyl peptidase-4 inhibitor sitagliptin phosphate, the glinides nateglinide and repaglinide, the glucagon-like peptide-1 derivative exenatide, and rapid-acting, bipbasic, and inhaled insulins.
Among the many important topics included in this program, Triplitt has conveniently organized and defined the medications that are used to treat type 2 diabetes into two major categories--those that substantially lower fasting glucose (including metformin, TZDs, sulfonylureas, Repaglinide and basal insulins) and those that substantially lower postprandial glucose levels (including Exenatide, Sitagliptin, Nateglinide, alpha-glucose inhibitors, prandial insulins and Pramlinitide).
Hypoglycemic episodes occurred more frequently with second-generation sulfonylureas and repaglinide than with metformin or thiazolidinediones, although there was wide variation in the risk levels reported from the different clinical trials.
The patients, aged between 33 and 80 years, had been diagnosed with type 2 diabetes for at least 1 year and had been using a combination of two oral antidiabetic agents (sulfonylurea or repaglinide plus thiazolidinedione or metformin) for at least 2 months.